Patterns of Care ConnectUS OncologyConnectUS Oncology
FCR/PCR3217184 R-Benda27333843 Rituximab14211824 Flu +/-
Ritux10513- Chlorambucil753- First Line Therapy Second Line Therapy
1)Sharman et al ASH 2011 2)Market Connect / McKesson Specialty
Health
Slide 6
Single agent idelalisib 101-02 Study Brown et al Blood
2014
Slide 7
Single agent idelalisib 101-02 Study
Slide 8
Idelalisib Combination 101-07 Study Sharman et al ASH 2011
Slide 9
Idelalisib Combination 101-07 Study Sharman et al ASH 2011
Slide 10
CLL Registration Study
Slide 11
Healthy Volunteer Trials Dose-ranging Metabolism Hematologic
Cancer Trials Single-agent (101-02 Study) Combination (101-07
Study) Combination (101-08 Study) Full Development 2011-2016 Early
Development 2008-2010 Refractory iNHL Phase 2 single-agent (101-09
Study) Previously treated iNHL Phase 3 combination immuno or
chemoimmunotherapy 124 Study: R GS-1101 125 Study: BR GS-1101 iNHL
Accelerated Approval iNHL Full Approval Previously treated CLL
Phase 3 combination with CD-20 mAb 116/117 Study: R GS-1101 119
Study: Ofa GS-1101 CLL Full Approval Additional studies lymphoid
malignancies Exploration & Indication Expansion Previously
treated CLL Phase 3 combination with chemoimmunotherapy 115 Study:
BR GS-1101 Study Context
Slide 12
Slide 13
in patients for whom rituximab alone would be considered
appropriate therapy due to other comorbidities
CharacteristicPercentageMedian Age > 6578%71 Cr Clearance <
6040%64 ml/min Grade 3 Marrow35% CIRS > 685%8